News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trimel Pharmaceuticals (Formerly Known As Trimel BioPharma) (TRL.TO) Announces Closing Of $10.5 Million Private Placement Of Common Shares


2/24/2014 7:38:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Trimel Announces Closing of $10.5 Million Private Placement of Common Shares

TORONTO, ONTARIO--(Marketwired - Feb 21, 2014) - Trimel Pharmaceuticals Corporation (TRL.TO) announced today that the previously disclosed private placement of 14,829,676 common shares ("Common Shares"), in aggregate, to First Generation Capital Inc. and West Face Long Term Opportunities Global Master L.P. for total gross proceeds of $10,543,000 has been completed.

"We would like to thank each of the subscribers for their continuing support," stated Tom Rossi, President and Chief Executive Officer. "These funds will allow management to focus their efforts on achieving the key operational objectives and milestones of the company over the coming months."

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRTâ„¢, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

Contact:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES